Loading…
DLG Naturals, Inc. was cited for selling four botanical products—Nilotica East African Shea Butter, Kalahari Melon Seed Oil, Baobab Oil, and Kigelia Africana Fruit Extract—as unapproved new drugs in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act. The company made disease treatment and body function claims on its website (such as therapeutic properties for Baobab Oil) that caused these products to qualify as drugs under FDA definition, yet they lacked required FDA approval before being marketed and sold. The violations were identified during a facility inspection in September-October 2021 and confirmed through a subsequent review of the company's website in March 2022.